Michael Alfieri bought $13k of ALDX
Principal Financial Officer at Aldeyra Therapeutics, Inc.. 2,500 shares at an average of $5.30, traded Aug 13, 2025, filed Aug 15, 2025.
Score components
- +15RoleOfficer
- 0Trade size$13k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +4Price context23% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-109391, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 13, 2025 | POpen-market purchase Common Stock | +2,500 | $5.30 | $13k | 2,500 | Aug 15, 2025 |
Related signals
Other insiders at Aldeyra Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 25Weak | ALDXsell Aldeyra Therapeutics, Inc. | Stephen Machatha Chief Development Officer | $114k 22,073 shares | -9% | |
| 47Moderate | ALDXsell Aldeyra Therapeutics, Inc. | Perceptive Advisors LLC owner | $4.8M 3,400,000 shares | -37% | |
| 23Weak | ALDXbuy Aldeyra Therapeutics, Inc. | Nancy Miller-Rich director | $10k 922 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.